COMPANY
More

Fate expands stem cell modulator pipeline, acquires Verio Therapeutics. Press release and Xconomy article.

Technology Review selects Fate as one of the 50 most innovative companies in the world

Fate receives the Red Herring North America 100 Award

Forbes names Fate as a Company to Watch on December 24, 2009

In November 2009, Fate closed a $30 million Series B financing.

Fierce Biotech covers Fate as an Emerging Drug Developer on September 21, 2009

THERAPEUTIC AREAS
More

Xconomy reports that Fate starts first clinical trial of FT1050 on May 27, 2009

Read the press release announcing the treatment of the first patient in Phase Ib

Fate describes their approach to Stem Cell Modulation in Drug Discovery Today on August 25, 2009

Bloomberg covers Fate on July 9, 2009

Wired Science covers FT1050 on June 9, 2009: Forgotten Drug Helps Stem Cells Repair Bone Marrow

IPSC TECHNOLOGY
More

Read how Fate is using iPSCs to find new medicines

BusinessWeek reports on Fate receiving Notice of Allowance for first U.S. patent for iPSC technology on February 4, 2010

Read the press release on the Notice of Allowance

The Scientist recognized protein-only reprogramming as The Top Innovation of 2009

iPSC RESEARCH ADVANCES

”A chemical platform for improved induction of human iPSCs” in Nature Methods

Read More iPS Cells in Less Time in SciBx covering the Nature Methods research

“Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins” in Cell Stem Cell

Explore chemical approaches to stem cell biology in a review in Nature

“In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state” in Nature